ICTRP Search Portal

Main

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.

Register:	German Clinical Trials Register
Last refreshed on:	8 April 2024
Main ID:	DRKS00014817
Date of registration:	11/06/2018
Prospective Registration:	No
Primary sponsor:	FUTURUM - Jönköping Academy of Health and Care Jönköping County Council
Public title:	Narrowband-UVB treatments effect on S100A8/A9 protein and gene expression in psoriasis skin and serum in individuals with plaque psoriasis.
Scientific title:	Narrowband-UVB treatments effect on S100A8/A9 protein and gene expression in psoriasis skin and serum in individuals with plaque psoriasis. - PSOKAL
Date of first enrolment:	09/12/2013
Target sample size:	25
Recruitment status:	Complete
URL:	http://drks.de/search/en/trial/DRKS00014817
Study type:	observational
Study design:	Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: other
Phase:

Countries of recruitment
Sweden

Contacts

Name:	Albert Duvetorp
Address:	Hudkliniken SUS malmö, Jan waldenströmsgata 18 21428 Malmö Sweden
Telephone:	+46736166946
Email:	albert.duvetorp@skane.se
Affiliation:	IKE Linköpings Universitet, Skåne University Hospital Malmö

Name:	Oliver Seifert
Address:	Hudkliniken, Sjukhusgatan, 55305 Jönköping Sweden
Telephone:	+46706301079
Email:	oliver.seifert@rjl.se
Affiliation:	IKE Linköping Sweden

Key inclusion & exclusion criteria

Inclusion criteria: Plaque psoriasis
Exclusion criteria: Pregnancy
Other chronic inflammatory disease
Psoriasis Arthritis (Active)
Ongoing infection
Systemic psoriasis treatment
Recent high UV exposure
Unability to give informed consent to study

Age minimum: 18 Years
Age maximum: None
Gender: All

Health Condition(s) or Problem(s) studied

L40

Psoriasis

Intervention(s)

Group 1: S100A8/A9 gene expression and protein expression levels in lesional, non-lesional skin and blood are studied in Swedish plaque psoriasis patients receiving narrowband UVB treatment (20-25 treatment sessions). Disease activity is monitored using psoriasis area severity index (PASI). We observe the dynamics of S100A8/A9 in response to treatment and PASI change.

Primary Outcome(s)

Gene and protein expression of S100A8/A9 in response to disease improvement measured with psoriasis area severity index (PASI). Skin levels (biopsies) are performed before and after a complete NB-UVB treatment (20-25 sessions). Serum samples are taken after every 5 NB-UVB sessions.

Secondary Outcome(s)

Is serum S100A8/A9 a potential Clinical biomarker for psoriasis disease activity?

Secondary ID(s)

Source(s) of Monetary Support

FUTURUM - Jönköping Academy of Health and CareJönköping County Council

Secondary Sponsor(s)

Ethics review

Status: Approved
Approval date: 23/01/2013
Contact:

anna.alexandersson@linkoping.epn.se

Linköpings universitet (University of Linköping)Regionala etikprövningsnämnden i Linköping, c/o Hälsouniversitetets kansli [EPN Regional ethical board of Linköping. "Regionala etikprövningsnämnden i Linköping"]

+46 (0)10-1037030

anna.alexandersson@linkoping.epn.se

Results

Results available:
Date Posted:
Date Completed:	15/06/2016
URL:	http://drks.de/search/en/trial/DRKS00014817#studyResults

Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.